| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0bddb695331af9b1a351ec38b1476e85
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0d39573398ad3a0a5d94465e4356d024
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_82ce993b8e3f93031578cb446d1e9a6d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1b93d93c9c6b701bcdf12fd3ea690e47
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_690599b7e00c5a0076d846def4395d28 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-0086
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2205-84
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2202-064
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-0083
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M2250-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-009
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-002
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61M15-0066
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-48 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01N43-58 |
| filingDate |
2010-06-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d03daf6603418d9e3849739f3a2edc27
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99683a196bd423355864fac29b601727
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e1a3bbe1bb9553fdf0e48614f38677ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6380d5dfb656dd2e358588a345dde1a5 |
| publicationDate |
2010-12-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2010151804-A1 |
| titleOfInvention |
Administration of dihydroergotamine mesylate particles using a metered dose inhaler |
| abstract |
Disclosed are compositions of matter and related methods that provide a metered dose inhaler that includes a formulation having a dose that comprises a hydrofluoroalkane propellant and dihydroergotamine mesylate particles; wherein the dose includes between 0.1 mg to 4 mg of dihydroergotamine mesylate; wherein the dihydroergotamine mesylate particles have a cumulative drug substance particle size distribution with d10 > 0.5 micron volumetric median diameter and d90 < 5.0 micron volumetric median diameter. |
| priorityDate |
2009-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |